Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Xcel Research LLC

Has Xcel Research LLC received an FDA warning letter? Yes. FDA issued a warning letter dated December 10, 2024 concerning products containing retatrutide and semaglutide and mazdutide and survodutide.

Letter facts

Letter date
December 10, 2024 (2024-12-10)
Issuing office
Center for Drug Evaluation and Research (CDER)
Products named
RETA (Retatrutide)CagriLean (Cagrilintide and Semaglutide)CAGRILINTIDEMAZDUTIDESEMA (Semaglutide)SURVODUTIDESERMORELIN
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA found the website sells retatrutide, semaglutide, cagrilintide, mazdutide, survodutide and sermorelin as unapproved new drugs, with claims showing intended human use despite research-use-only labeling.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Unapproved new drugs (FD&C Act sections 505(a) and 301(d))
  • Drug claims despite research-use-only labeling

More letters about Cagrilintide

Recent FDA warning letters concerning Cagrilintide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.